Co-relation of SARS-CoV-2 Related 30-d Mortality with HRCT Score and RT-PCR Ct Value-based Viral Load in Patients with Solid Malignancy

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2022 Jun 6

PMID 35662981

Authors

Satya Narayan

Vineet Talwar

Varun Goel

Krushna Chaudhary

Anurag Sharma

Pallavi Redhu

Satyajeet Soni

Arpit Jain

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 2019 (COVID-19) patients with malignancy are published worldwide but are lacking in data from India.

Aim: To characterize COVID-19 related mortality outcomes within 30 d of diagnosis with HRCT score and RT-PCR Ct value-based viral load in various solid malignancies.

Methods: Patients included in this study were with an active or previous malignancy and with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the institute database. We collected data on demographic details, baseline clinical conditions, medications, cancer diagnosis, treatment and the COVID-19 disease course. The primary endpoint was the association between the mortality outcome and the potential prognostic variables, specially, HRCT score, RT-PCR Ct value-based viral load, using logistic regression analyses treatment received in 30 d.

Results: Out of 131 patients, 123 met inclusion criteria for our analysis. The median age was 57 years (interquartile range = 19-82) while 7 (5.7%) were aged 75 years or older. The most prevalent malignancies were of GUT origin 49 (39.8%), hepatopancreatobiliary (HPB) 40 (32.5%). 109 (88.6%) patients were on active anticancer treatment, 115 (93.5%) had active (measurable) cancer. At analysis on May 20, 2021, 26 (21.1%) patients had died. In logistic regression analysis, independent factors associated with an increased 30-d mortality were in patients with the symptomatic presentation. Chemotherapy in the last 4 wk, number of comorbidities (≥ 2 none: 3.43, 1.08-8.56). The univariate analysis showed that the risk of death was significantly associated with the HRCT score: for moderate (8-15) [odds ratio (OR): 3.44; 95% confidence interval (CI): 1.3-9.12; = 0.0132], severe (> 15) (OR: 7.44; 95%CI: 1.58-35.1; = 0.0112).

Conclusion: To the best of our knowledge, this is the first study from India reporting the association of HRCT score and RT-PCR Ct value-based 30-d mortality outcomes in SARS-CoV-2 infected cancer patients.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Shi F, Wu T, Zhu X, Ge Y, Zeng X, Chi Y . Association of viral load with serum biomakers among COVID-19 cases. Virology. 2020; 546:122-126. PMC: 7192122. DOI: 10.1016/j.virol.2020.04.011. View

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A . Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020; 10(7):935-941. PMC: 7334098. DOI: 10.1158/2159-8290.CD-20-0516. View

Huang J, Ran R, Lv Z, Feng L, Ran C, Tong Y . Chronological Changes of Viral Shedding in Adult Inpatients With COVID-19 in Wuhan, China. Clin Infect Dis. 2020; 71(16):2158-2166. PMC: 7314240. DOI: 10.1093/cid/ciaa631. View

Klein S, Flanagan K . Sex differences in immune responses. Nat Rev Immunol. 2016; 16(10):626-38. DOI: 10.1038/nri.2016.90. View

Levin B, Antia R . Why we don't get sick: the within-host population dynamics of bacterial infections. Science. 2001; 292(5519):1112-5. DOI: 10.1126/science.1058879. View

Azzi L, Carcano G, Gianfagna F, Grossi P, Dalla Gasperina D, Genoni A . Saliva is a reliable tool to detect SARS-CoV-2. J Infect. 2020; 81(1):e45-e50. PMC: 7194805. DOI: 10.1016/j.jinf.2020.04.005. View

Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J . Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63(3):364-374. PMC: 7088566. DOI: 10.1007/s11427-020-1643-8. View

10.

Karahasan Yagci A, Sarinoglu R, Bilgin H, Yanilmaz O, Sayin E, Deniz G . Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain reaction and total severity score of computerized tomography in patients with COVID 19. Int J Infect Dis. 2020; 101:160-166. PMC: 7521909. DOI: 10.1016/j.ijid.2020.09.1449. View

11.

Shah S, Singhal T, Davar N, Thakkar P . No correlation between Ct values and severity of disease or mortality in patients with COVID 19 disease. Indian J Med Microbiol. 2021; 39(1):116-117. PMC: 7667391. DOI: 10.1016/j.ijmmb.2020.10.021. View

12.

Waller J, Allen I, Lin K, Diaz M, Henry T, Hope M . The Limited Sensitivity of Chest Computed Tomography Relative to Reverse Transcription Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus-2 Infection: A Systematic Review on COVID-19 Diagnostics. Invest Radiol. 2020; 55(12):754-761. PMC: 7314354. DOI: 10.1097/RLI.0000000000000700. View

13.

Zheng Y, Ma Y, Zhang J, Xie X . COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17(5):259-260. PMC: 7095524. DOI: 10.1038/s41569-020-0360-5. View

14.

Pan F, Ye T, Sun P, Gui S, Liang B, Li L . Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020; 295(3):715-721. PMC: 7233367. DOI: 10.1148/radiol.2020200370. View

15.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

16.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

17.

Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B . How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015; 14(3):309-21. PMC: 4406660. DOI: 10.1111/acel.12326. View

18.

Rao S, Manissero D, Steele V, Pareja J . A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther. 2020; 9(3):573-586. PMC: 7386165. DOI: 10.1007/s40121-020-00324-3. View

19.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

20.

Feikin D, Alraddadi B, Qutub M, Shabouni O, Curns A, Oboho I . Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. Emerg Infect Dis. 2015; 21(11):2029-35. PMC: 4622256. DOI: 10.3201/eid2111.150764. View